Your SlideShare is downloading. ×
3 Horrendous Healthcare Stocks This Week   2-21-14
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

3 Horrendous Healthcare Stocks This Week 2-21-14

8,395
views

Published on

Which healthcare stocks were the worst of the worst this week?

Which healthcare stocks were the worst of the worst this week?

Published in: Health & Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
8,395
On Slideshare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
2
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • Transcript

    • 1. 3 Horrendous Health-Care Stocks This Week
    • 2. While the victors celebrated in Sochi this week, some Olympians felt the agony of defeat. The same was true in the world of health care. Source: Wikimedia Commons.
    • 3. Onconova Therapeutics (Nasdaq: ONTX) The stock of the biopharmaceutical firm focusing on cancer drugs plunged nearly 38% for the week.
    • 4. Why Onconova nosedived • It announced disappointing results for phase 3 study of rigosertib. • Rigosertib failed to meet its primary endpoint of median overall survival. • The study focused on use of the drug in the treatment of myelodysplastic syndrome, or MDS, in high-risk patients. • Another phase 2 study is under way for rigosertib in treating lower-risk MDS patients.
    • 5. Medbox (NasdaqOTH: MDBX) Shares of this medical marijuana dispensing equipment maker careened more than 24% this week.
    • 6. Why Medbox shares got clobbered • The company was the target of a damaging online article by Citron Research’s Andrew Left. • Left called Medbox’s stock “worthless” and accused the company of fraud. • Medbox publicly acknowledged some accounting errors that were corrected. • Medbox’s largest shareholder and chairman, Vincent Mehdizadeh, responded with a scathing criticism of Andrew Left.
    • 7. GW Pharmaceuticals (Nasdaq: GWPH) The stock of the pharmaceutical firm focusing on medical marijuana fell nearly 9% this week.
    • 8. Why GW shares weren’t buzzing • It was attacked by a short-seller, Infitialis, in a blog post. • The blogger listed multiple issues with GW Pharmaceuticals, including being overhyped as a marijuana play and overvalued. • The stock was hit hard initially, but recovered somewhat.
    • 9. Best shot at bouncing back? • None of this week’s horrendous stocks look very promising. • Onconova still has a phase 2 study under way for rigersitib in treating lower-risk MDS, but it’s probably something of a long shot. • While short-sellers attacking Medbox and GW Pharmaceuticals don’t have the purest of motives, both stocks do appear to be overvalued. • Investors probably should consider looking elsewhere.
    • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!